Human Immunology Biosciences, Inc.

I-Mab Advances Immunotherapy Pipeline with Uliledlimab, Givastomig, and Ragistomig

a year ago

• I-Mab is preparing to file an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors for newly diagnosed NSCLC patients in 1H 2024. • The first patient has been dosed in a triplet combination, dose escalation study of givastomig for gastric cancer and esophageal adenocarcinoma in 1Q 2024. • Strategic divestiture of assets and business operations in China is expected to close by the end of March 2024, impacting the company's financial condition. • I-Mab reported RMB2.3 billion (US$321.8 million) in cash, cash equivalents, and short-term investments as of December 31, 2023.